Approval time and agency of aprexitentan (Tryvio)

Aprocitentan-Tryvio is an innovative endothelin receptor antagonist that was approved for marketing by the U.S. Food and Drug Administration (FDA) on March 19, 2024, becoming an important new drug in the treatment of hypertension. This approval not only marks a breakthrough in drug mechanism innovation, but also reflects the urgent need for precision drugs in modern hypertension management.

For a long time, patients with hypertension, especially those with refractory hypertension who still have difficulty achieving blood pressure goals despite multiple drug combinations, have had limited clinical treatment options. The launch of aprecitentan provides a new treatment idea for these patients. By selectively blocking endothelin receptors, it reduces vasoconstriction and peripheral resistance, thereby effectively improving hemodynamics and reducing the risk of cardiovascular events such as stroke and myocardial infarction.

In the international market, aprecitentan is not currently available in the EU, and the European Medicines Agency (EMA) is evaluating its marketing application. Assessments include long-term safety, durability of efficacy, and accessibility in different populations. This approval process shows the cautious attitude of various regulatory agencies towards new hypertension drugs and also reflects the importance of international clinical data in global drug launches. The Chinese market has also not yet been launched, but with the acceleration of global drug development and introduction, the possibility of Aprexitentan being registered and approved in China is gradually increasing. If approved, it will provide new treatment options for domestic patients with refractory hypertension and may lead a new trend in combination drug regimens.

The approval of aprecitentan not only provides patients with new treatment options, but also provides a research and application reference for global hypertension management. Its precise mechanism, good tolerability and potential for combination therapy give it broad prospects in the treatment of resistant hypertension.

Reference materials:https://go.drugbank.com/drugs/DB15059